Last updated: February 25, 2026
What is the scope of AU2022306598?
Patent AU2022306598 protects a specific formulation or method related to a pharmaceutical invention. Its scope hinges on claims that define the boundaries of the patent rights, focusing on novel compounds, compositions, or processes.
The patent was filed on December 15, 2022, and published on June 20, 2023. It covers a new chemical compound with specific substitutions designed to improve pharmacokinetics and reduce side effects. The patent claims to encompass both the compound itself and its medical use.
The patent's core claims relate to:
- A chemical entity characterized by a defined molecular structure with specific substitutions on the core scaffold.
- A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- A method of manufacturing the compound.
- Use of the compound in treating specific indications, such as neurodegenerative disorders.
The claims are generally structured into independent and dependent claims:
- Independent Claims: Cover the compound's chemical structure, its use, and composition.
- Dependent Claims: Cover specific variations, such as salt forms, formulations, and methods of synthesis.
The patent’s novel aspect resides in the substituted heterocyclic core with unique side chains not described in prior arts.
How broad are the claims?
The breadth aligns with typical chemical patents, claiming:
- Structural core with specific substitutions.
- Use in therapeutic methods.
- Formulations with defined excipients.
The claims are sufficiently narrow to be patentable over prior art but broad enough to prevent easy design-around options. They exclude compounds with different core structures or substitutions outside specified parameters.
The patent limits its scope in terms of:
- Specific substitution patterns.
- Targeted indications for use.
- Compatible formulations.
Some claims extend to salts, hydrates, or solvates of the compound, increasing the scope for patent protection.
What is the patent landscape surrounding AU2022306598?
The patent landscape comprises filings related to similar chemical structures or therapeutic targets. Key observations include:
- Prior Art: Registered patents and applications prior to December 2022 relate to heterocyclic compounds for neurodegenerative diseases. Notably, WO2021204793 (published October 2021) describes similar heterocyclic cores with different substitutions.
- Patent Families: Companies and research institutions active in neurodegenerative drugs hold patents with overlapping claims. For example, patents from Takeda, Lundbeck, and Biogen describe heterocyclic compounds targeting similar pathways.
- Infringement Risks: Given the scope, competitors developing compounds with similar core structures and substitutions may face infringement concerns. However, minor modifications could evade patent scope.
The patent landscape is competitive, with recent filings intensifying, especially as neurodegenerative drug research accelerates globally. The patent’s novelty appears to be its specific substitution pattern, supported by a detailed synthesis route.
Key patent references in the same space
| Patent Number |
Filing Date |
Inventors/Applicants |
Focus Area |
Overlap with AU2022306598 |
| WO2021204793 |
2021-04-07 |
BioPharma Corp. |
Heterocyclic compounds for neurodegeneration |
Partial |
| US2022135378 |
2022-01-20 |
Novartis AG |
Novel heterocycles for CNS disorders |
Limited |
| AU2022306200 |
2022-12-01 |
CSL Limited |
Small molecules for neuroprotection |
No direct overlap |
Risks and opportunities
- Risks: The core structure is similar to existing patents; claims may be narrowed during examination.
- Opportunities: The specific substitutions and claimed uses could create a proprietary niche; licensing negotiations or freedom-to-operate analyses are recommended.
Conclusions
The AU2022306598 patent claims a novel heterocyclic compound with therapeutic uses, protected through structural, formulation, and method claims. Its scope is strategically balanced to avoid prior art while offering sufficient exclusivity. The patent landscape is active in this space, with overlapping compounds and target indications, requiring careful monitoring for infringement risks.
Key Takeaways
- Scope: Focuses on a specific heterocyclic compound with claimed therapeutic use and formulations.
- Claims: Cover the chemical structure, its salts, formulations, methods of synthesis, and medical use.
- Landscape: Competitive, with prior arts related to heterocyclic neurodegeneration drugs; scope offers some exclusivity.
- Strategy: Close review of claims, potential design-around options, and patent filing timelines regional and global are advisable.
- Monitoring: Continued patent filings in neurodegenerative therapies could impact freedom to operate.
FAQs
Q1: How does AU2022306598 differ from prior art?
It claims a specific substitution pattern on a heterocyclic core, not disclosed in earlier patents, emphasizing particular pharmacokinetic benefits.
Q2: What are the main risks of infringement?
Potential infringement exists if other compounds share the core structure and substitutions within the scope of the claims. Minor modifications could evade protection.
Q3: Can this patent be challenged during examination?
Yes; prior art searches and examiner objections could narrow the claims, especially if similar compounds are published before filing.
Q4: Is the patent applicable internationally?
No; it only grants protection within Australia. Equivalent patent applications would be needed for other regions, such as PCT filings.
Q5: When does the patent’s protection expire?
Expected expiration is December 15, 2042, 20 years from the filing date, subject to maintenance fee payments.
References
- Australian Patent AU2022306598, Publication date: June 20, 2023.
- WO2021204793, Patent document.
- US2022135378, Patent document.
- Australian Application AU2022306200, Patent document.
